- Home
- PFD vs MCRB Comparison
PFD vs MCRB Comparison
Compare PFD & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- MCRB
- Stock Information
- Founded
- PFD 1990
- MCRB 2010
- Country
- PFD United States
- MCRB United States
- Employees
- PFD N/A
- MCRB N/A
- Industry
- PFD Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- PFD Finance
- MCRB Health Care
- Exchange
- PFD Nasdaq
- MCRB Nasdaq
- Market Cap
- PFD 144.5M
- MCRB 141.9M
- IPO Year
- PFD N/A
- MCRB 2015
- Fundamental
- Price
- PFD $11.21
- MCRB $0.70
- Analyst Decision
- PFD
- MCRB Hold
- Analyst Count
- PFD 0
- MCRB 5
- Target Price
- PFD N/A
- MCRB $4.00
- AVG Volume (30 Days)
- PFD 33.2K
- MCRB 862.7K
- Earning Date
- PFD 01-01-0001
- MCRB 03-13-2025
- Dividend Yield
- PFD 6.30%
- MCRB N/A
- EPS Growth
- PFD N/A
- MCRB N/A
- EPS
- PFD N/A
- MCRB 0.00
- Revenue
- PFD N/A
- MCRB N/A
- Revenue This Year
- PFD N/A
- MCRB N/A
- Revenue Next Year
- PFD N/A
- MCRB N/A
- P/E Ratio
- PFD N/A
- MCRB $798.74
- Revenue Growth
- PFD N/A
- MCRB N/A
- 52 Week Low
- PFD $8.53
- MCRB $0.54
- 52 Week High
- PFD $11.18
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- PFD 45.97
- MCRB 44.30
- Support Level
- PFD $11.14
- MCRB $0.69
- Resistance Level
- PFD $11.35
- MCRB $0.76
- Average True Range (ATR)
- PFD 0.09
- MCRB 0.05
- MACD
- PFD -0.00
- MCRB 0.00
- Stochastic Oscillator
- PFD 37.50
- MCRB 42.13
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.